Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
10:26am, Friday, 17'th Jan 2025
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
US FDA declines to approve Atara Biotherapeutics' cancer therapy
08:41am, Thursday, 16'th Jan 2025
The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' cancer therapy, chemically called tabelecleucel.
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
08:30am, Thursday, 16'th Jan 2025
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Here's Why You Should Consider Buying Atara Biotherapeutics Stock
11:46am, Wednesday, 08'th Jan 2025
Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
01:10pm, Thursday, 02'nd Jan 2025
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
04:01pm, Wednesday, 27'th Nov 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
04:01pm, Wednesday, 13'th Nov 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
06:16pm, Tuesday, 12'th Nov 2024
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share versus the Zacks Consensus Estimate of a loss of $3.77. This compares to loss of $16.50 per share a year ago.
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
04:01pm, Tuesday, 12'th Nov 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know
01:00pm, Tuesday, 15'th Oct 2024
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 04'th Oct 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
07:10pm, Monday, 12'th Aug 2024
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $3.10 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $17 per share a year ago.
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
05:00pm, Monday, 12'th Aug 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
01:01pm, Monday, 15'th Jul 2024
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 05'th Jul 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
